Barbara Formisano

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.

Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.

Journal: International journal of cancer

Published: June 18, 2023

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.

Journal: Therapeutic advances in medical oncology

Published: December 05, 2022

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.

Journal: Future oncology (London, England)

Published: February 19, 2016

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.

Journal: Oncotarget

Published: December 14, 2015

Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.

Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.

Journal: Future oncology (London, England)

Published: July 11, 2015

Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.

Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.

Journal: Tumori

Published: February 18, 2015

Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.

Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.

Journal: American journal of clinical oncology

Published: February 23, 2013

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.

Journal: Translational oncology

Published: March 07, 2012

Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?

Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?

Journal: Tumori

Published: December 14, 2011

Showing 1-9 of 9

Last Updated: 09/26/2026